Podcast Music Movie Game Book
  1. 🎧Podcast
  2. 🎧U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  3. FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

Release Date:

FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation.

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

Title
FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer
Copyright
Release Date

flashback